The Priority Review

Tag

pimicotinib

1 story

Stories

  1. Approvals

    FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor

    On November 10, 2026, the FDA approved pimicotinib (Pimjetmi, EMD Serono, Inc.) for adults with symptomatic TGCT for whom surgical resection may cause worsening functional limitation or severe morbidity. The approval follows a double-blind, randomized, placebo-controlled MANEUVER trial that evaluated pimicotinib 50 mg once daily.